Skip to content
MarketScale
‹ Back to IndustriesHealthcare

U.S. Made Medical Devices Deliver Economic and Innovative Benefits

While the U.S. was once a predominant power in manufacturing, that changed when manufacturers started off-shoring to reduce costs, mostly related to labor, during the 1970s. However, because there are many advantages for manufacturers to conduct business in the U.S., some manufacturing companies are choosing to re-shore here at home. One industry that the U.S….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

While the U.S. was once a predominant power in manufacturing, that changed when manufacturers started off-shoring to reduce costs, mostly related to labor, during the 1970s. However, because there are many advantages for manufacturers to conduct business in the U.S., some manufacturing companies are choosing to re-shore here at home. One industry that the U.S. continues to lead in manufacturing, though, is the medical device sector—a segment that not only continues to support innovation, but is vital to our economy as well.

Medical device industry yields major economic benefits

The U.S. represents about 40% of the medical device market.[1] It also employs a significant number of people. According to the 2012 Economic Census, over 350,000 Americans work in the medical device industry. These workers also earn on average 15% more than other manufacturing jobs. While there are 5,800 medical device establishments across the U.S., 80% of these employ fewer than 50 employees.[2] This figure indicates that medical device manufacturing plays a prominent role in the country’s small business segment, including many startups.

Innovation, R&D efforts propel medical device industry

Known for its research and development efforts, medical device manufacturing is an industry that keeps moving forward. Compared to comparable industries, medical device companies invest a higher percentage of annual revenue into new product design. In fact, according to the ITA, this commitment is reflected in the spending of 6.7% of revenue from 2011 to 2016 for R&D alone.[3] And with each company striving to find the next breakthrough, intense competition continues to propel the industry further.

The medical device sector also continues to benefit from a new generation of materials, manufacturing processes, and technology, such as nanotechnology and micro-electro-mechanical systems (MEMS). Recent products introduced include neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Innovation fuels the medical device sector’s ongoing quest to improve and maintain the health of the world.

This innovative spirit and dedication to research and development is also impacting re-shoring. The competitive advantages, including a highly skilled workforce, have manufacturers bringing operations back to the U.S. According to the Reshoring Initiative, the American manufacturing industry has seen an increase of over 500,000 jobs created since the recession.[4]

The Future of Medical Device Manufacturing

Although, manufacturing in the U.S. has been on a steady decline over the last few decades, medical device manufacturing continues to grow, innovate, and lead the world. American-made medical devices are not only vital to our nation’s healthcare industry, but of great importance to the country’s economic well-being as well.

As a single source manufacturer, Ranfac does everything from raw material to final packaging under one roof. Our products have been 100% manufactured in the U.S. since 1888. We work with our healthcare partners and medical device companies to bring to market single-use medical devices for a vast range of specialties. Learn more about our development process by watching this video.

Read more at ranfac.com

[1]https://www.trade.gov/topmarkets/pdf/Medical_Devices_Top_Markets_Report.pdf

[2]https://www2.census.gov/library/publications/2011/compendia/statab/131ed/2012-statab.pdf

[3] https://www.selectusa.gov/medical-technology-industry-united-states

[4] http://www.reshorenow.org/

0 Likes

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512